Gossamer Bio (GOSS) Total Liabilities (2018 - 2026)

Gossamer Bio has reported Total Liabilities for 9 years, with the latest figure at $170.9 million in Q2 2026.

• On a quarterly basis, Total Liabilities fell 40.46% year-over-year to $170.9 million in Q2 2026; TTM through Jun 2026 was $170.9 million, a 40.46% decrease from a year earlier, with the FY2025 full-year figure at $295.0 million, up 3.22% from the prior year.
• Total Liabilities was $170.9 million for Q2 2026 at Gossamer Bio, down from $290.4 million in the prior quarter.
• The five-year high for Total Liabilities was $296.7 million in Q3 2024, with the low at $170.9 million in Q2 2026.
• Average Total Liabilities over 5 years is $264.9 million, with a median of $265.9 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: Total Liabilities grew 25.73% in 2022, then tumbled 40.46% in 2026.
• Over 5 years, Total Liabilities stood at $260.4 million in 2022, then declined by 4.31% to $249.1 million in 2023, then grew by 14.71% to $285.8 million in 2024, then gained by 3.22% to $295.0 million in 2025, then sank by 42.07% to $170.9 million in 2026.
• The last three Total Liabilities figures came in at $170.9 million (Q2 2026), $290.4 million (Q1 2026), and $295.0 million (Q4 2025), per Business Quant data.